Sign In
Buy GLPG
$27.38
+0.0650 (+0.238%)
At Close: Jun 03, 2026
Galapagos Creates New Subscription Right Plan
04:01pm, Friday, 06'th Mar 2026
Mechelen, Belgium; March 6, 2026, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,750,000 subscription rights unde
Galapagos Appoints Tania Philipp as Chief Human Resources Officer
04:01pm, Thursday, 05'th Mar 2026
Seasoned Life Sciences Executive Joins Galapagos with Strong Track Record in Change Management Mechelen, Belgium; March 5, 2026, 22:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG) today announced th
Galapagos Receives Transparency Notifications from Bank of America
04:01pm, Wednesday, 04'th Mar 2026
Mechelen, Belgium ; March 4, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America.
Galapagos NV (GLPG) Q4 2025 Earnings Call Transcript
01:38pm, Tuesday, 24'th Feb 2026
Galapagos NV (GLPG) Q4 2025 Earnings Call Transcript
Galapagos Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
04:01pm, Monday, 23'rd Feb 2026
Mechelen, Belgium; February 23, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today reported its financial results for the full year 2025 and provided an update on
Galapagos Receives Transparency Notification from Bank of America
04:01pm, Monday, 16'th Feb 2026
Mechelen, Belgium ; February 16, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Bank of America.
Stock Market Today: Dow Jones Futures Drop After Scaling Record Highs— CoreWeave, Vistra, Microchip Technology In Focus
05:10am, Tuesday, 06'th Jan 2026
U.S. stock futures were mixed on Tuesday after a higher close on Monday.
AngioDynamics, Microchip Technology And 3 Stocks To Watch Heading Into Tuesday
02:55am, Tuesday, 06'th Jan 2026
U.S. stock futures up, focus on AngioDynamics, Microchip Tech, AAR earnings. Galapagos to wind down cell therapy.
Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities
04:01pm, Monday, 05'th Jan 2026
Mechelen, Belgium ; January 5, 2026, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the works council consultation process regarding the wind-down of cell therapy activities ha
Galapagos: Pivoting From Clinical Risk To Strategic Capital Allocation
05:39am, Monday, 22'nd Dec 2025
Galapagos now presents a deep value opportunity, underpinned by a €3B cash reserve and a decisive shift to capital allocation discipline. GLPG's restructuring—discontinuing cell therapy, slashing
Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025
01:30am, Monday, 08'th Dec 2025
High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell the
Galapagos Receives Transparency Notifications from Bank of America
01:30am, Wednesday, 26'th Nov 2025
Mechelen, Belgium ; November 26, 2025, 07:30 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America.
Galapagos NV (GLPG) Q3 2025 Earnings Call Transcript
03:36pm, Thursday, 06'th Nov 2025
Galapagos NV ( GLPG ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Glenn Schulman Henry Gosebruch - CEO & Executive Director Aaron Cox - Chief Financial Officer Dan Grossman
Galapagos to Present New Data from Cell Therapy Program at ASH 2025
04:01pm, Monday, 03'rd Nov 2025
Oral presentation of GLPG5101 data from the ATALANTA-1 study in patients with high-risk relapsed/refractory mantle cell lymphoma
Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors
04:01pm, Thursday, 23'rd Oct 2025
Mechelen, Belgium ; October 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new in vitro pharmacological data from its selective TYK2 inhibitor, GLPG36
